Business
Mushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update
Mushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update.
About this update from Mushrooms, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Mushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update\r\n \r\n \r\n\r\n\r\nMushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update\r\n\r\n\r\n\r\n\r\n\r\nESTERO, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- Mushrooms Inc. (OTC: MSRM) today announced the successful early-stage validation of its mycelium-based infection detection technology and the completion of beta testing for its MycoLab.ai research platform, marking a significant advancement in the development of its MycoLabX platform. These milestones strengthen the company’s position in emerging fungal biotechnology and biomaterials innovation and have led the company to reassess its strategic options and the structure of the previously announced strategic transaction with SecurCapital Corp. Technology Milestone and Patent SectionOver the past weeks, MycoLabX has achieved an important technical milestone in collaboration with the company’s research team in Germany. Prototype testing successfully demonstrated a visible color-change response when the company’s mycelium-based films were exposed to bacterial activity, confirming the core sensing mechanism underlying the company’s infection-detection biomaterials platform. This milestone represents successful early-stage proof of concept, validating the foundational biological response central to the company’s patent-pending technology. The observed biological response supports the company’s approach, which utilizes engineered mycelium-derived biomaterials designed to react to bacterial presence and provide a visual indication of infection. Following this initial validation, the company is preparing for the next phase of development, which is expected to include expanded testing and third-party validation initiatives, including evaluation pathways with leading U.S. research and defense-related institutions. This successful early validation represents a key milestone toward the development of next-generation biomaterials capable of detecting infection in wound care, medical monitoring, and related healthcare applications. The company believes such technologies may ultimately support future regulatory pathways applicable to biome...